NICE rejects Roche's Avastin for metastatic colorectal cancer, again
This article was originally published in Scrip
Executive Summary
NICE, the National Institute of health and Clinical Excellence in England and Wales, has again rejected Roche's Avastin (bevacizumab) for metastatic colorectal cancer. An amended patient access scheme submitted by the company failed to convince the institute that the drug would be a cost-effective use of NHS resources.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.